Targeting Hallmarks of Cancer

Guest Editor:

Prof. Dr. Carlos Pérez Plasencia

1. Laboratorio de Genómica, Instituto Nacional de Cancerología, Tlalpan 14080, México
2. Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Tlalnepantla 54090, Mexico

Deadline for manuscript submissions:
25 April 2025

Message from the Guest Editor

Dear Colleagues,

Cancer remains one of the most significant challenges in modern medicine, characterized by its complexity, heterogeneity, and ability to evolve rapidly. The pursuit of new, efficient drugs to combat cancer is a top priority in biomedical research. However, the development of such therapies is not a straightforward process. It requires a deep understanding of the fundamental mechanisms driving cancer progression, including the hallmark traits of cancer cells and the intricate signaling pathways involved in maintaining the tumor phenotype. In this context, the creation and utilization of biological models, such as organotypic cell cultures, and the study of epigenetic regulators, like long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are crucial for advancing our ability to develop effective anti-cancer drugs.

You may choose our Joint Special Issue in *Cancers*.

Prof. Dr. Carlos Pérez Plasencia
Guest Editor

mdpi.com/si/218184

Special Issue

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us